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More than a decade ago, sirtuins were discovered as a highly conserved family of NAD+-
dependent enzymes that extend lifespan in lower organisms. In mammals, sirtuins are key
regulators of stress responses and metabolism, inﬂuencing a range of diseases, including
diabetes, neurodegeneration, and cancer. In recent years, new functions of sirtuins have
been characterized, uncovering the underlying mechanisms of their multifaceted role in
metabolism. Here, we speciﬁcally review recent progress on the role of sirtuins in DNA
repair and energy metabolism, further discussing the implication of sirtuins in the biology
of cancer.
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INTRODUCTION
Cancer can be deﬁned as an uncontrolled proliferation of cells in
thebody.Cells becomemalignant by the acquisitionof a succession
of capabilities that allows them to evade strict regulatory circuits
governing cell proliferation and homeostasis (Hanahan andWein-
berg, 2011). On their way to tumorigenesis, genomic instability
fuels the acquisition of these tumoral capabilities by generating
a genomic environment highly propitious to mutations. Among
the hallmarks of cancer cells, metabolic reprogramming stands
high, allowing these cells to face up to new energetic requirements.
While under normal conditions cells rely on mitochondrial oxida-
tive phosphorylation to produce energy from glucose, cancer cells
exhibit enhanced glycolysis. Simply put, pyruvate generated from
glucose is directed toward production of lactate in the cytosol
instead of entering the TCA cycle in the mitochondria. Because
oxygen is limiting during oxidation of pyruvate to CO2 in the
mitochondria, anaerobic glycolysis is usually activated in normal
cells under low oxygen conditions. However, cancer cells switch
their metabolism to glycolysis even under normoxic conditions,
in a process that only generates 2mol of ATP per mol of glu-
cose whereas oxidative phosphorylation generates up to 36mol of
ATP per mol of glucose. This process is known as the Warburg
effect after Otto Warburg, who observed in the 1920s that can-
cer cells metabolize tenfold more glucose to lactate than normal
cells, even in the presence of sufﬁcient oxygen to support oxidative
phosphorylation (Warburg et al., 1924). Although aerobic glycol-
ysis is highly inefﬁcient for ATP production, it is thought to be an
anaplerotic reaction that supplies critical intermediate metabolites
for biomass production (amino acids, lipids, and nucleotides),
imperative in highly proliferating cells (Vander Heiden et al.,
2009). In addition, such metabolic shift may also confer a sur-
vival advantage to tumor cells, given their characteristic hypoxic
environment.
Cells in an organism are subjected to stress arising from nutri-
ent ﬂuctuations as well as from genotoxic damage that menace
genome integrity. A proper cellular response to stress is essen-
tial to avoid transformation. Studies over the last decade strongly
indicate that sirtuins may play a fundamental role in this process.
Sirtuins are a highly conserved family of proteins, homologs of the
Saccharomyces cerevisiae protein Sir2 (Finkel et al., 2009). They are
nicotinamide adenine dinucleotide (NAD+)-dependent protein
deacetylases and/or mono-[ADP-ribosyl] transferases. Mammals
contain seven sirtuins (SIRT1–7) with different subcellular local-
ization; SIRT1, SIRT6, and SIRT7 are nuclear, SIRT2 is mainly
cytoplasmic and SIRT3, SIRT4, and SIRT5 are located in the
mitochondria (Finkel et al., 2009). Nowadays, sirtuins are rec-
ognized as crucial regulators of energy metabolism, working as
stress adaptors (oxidative, genotoxic and metabolic stress) likely
through sensing changes in levels of intracellular NAD+, an oblig-
ated cofactor for their enzymatic activity. As the best-studied
sirtuin, SIRT1 has been implicated in a large variety of meta-
bolic processes, in particular in the regulation of glucose and lipid
metabolism during fasting and caloric restriction. Several lines of
evidence also point to a fundamental role of SIRT3 and SIRT6
in the regulation of glucose utilization (Zhong and Mostoslavsky,
2011). These three sirtuins have also been shown to protect from
genomic instability upon genotoxic and oxidative stress, protect-
ing the genome from mutations that can drive tumorigenesis. In
this review we will summarize current advances in the biology of
these sirtuins.
SIRTUINS IN GLUCOSE METABOLISM AND DNA DAMAGE
SIRT1
During fasting, an increase in pyruvate and NAD+ levels induces
expression and activity of SIRT1 in hepatocytes promoting the
deacetylation of PGC-1α, a transcriptional co-activator of a large
number of genes (Figure 1). Deacetylation of PGC-1α results
in the induction of gluconeogenic genes and repression of gly-
colytic genes (Rodgers et al., 2005). In parallel, SIRT1 activates
the transcription factor FOXO1, which induces the same switch in
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transcription, reinforcing gluconeogenesis (Frescas et al., 2005)
(Figure 1). In muscle, like in liver, SIRT1-mediated activation
of PGC-1α during fasting activates peroxisome proliferators-
activated receptor α (PPARα)-mediated transcription of fatty-acid
catabolic genes (Gerhart-Hines et al., 2007; Purushotham et al.,
2009). Concretely, the activation of PGC-1α in muscle induces the
transcription of genes involved in mitochondrial oxidative phos-
phorylation and electron transport, coupling fatty-acid oxidation
with energy production. In this manner, activation of SIRT1 in
muscle coordinates a shift toward preservation of glucose in the
cell, while lipids are used to obtain energy. In white adipose tissue,
SIRT1 represses PPARγ during fasting, in turn inducing lipoly-
sis and reducing fat storage (Picard et al., 2004). Lastly, SIRT1
also protects from the negative effects of high fat diet (HFD),
stimulating secretion of insulin by pancreatic β-cells through
PPARγ-mediated transcriptional repression of uncoupling pro-
tein 2 (UCP2), improving in this way glucose tolerance (Moynihan
et al., 2005; Bordone et al., 2006) (Figure 1).
Although SIRT1 null mice die perinatally due to developmental
defects, absence of SIRT1 provokes a large amount of chromosome
abnormalities in embryos, impairing progression of cells through
mitosis (Wang et al., 2008). A defective signaling of DNA double-
strand breaks (DSBs) seems to be the cause behind this genomic
instability. SIRT1 associates with and deacetylates the repair factor
NBS1, a modiﬁcation required for its subsequent phosphoryla-
tion by theAtaxia Telangiectasia Mutated (ATM) kinase in the ﬁrst
steps of the DNA damage response (Yuan et al., 2007) (Figure 1).
In addition, SIRT1 is also recruited to DNA DSBs in an ATM-
dependent manner. The recruitment of SIRT1 at the breaks is
important for the accumulation of proteins involved in signal-
ing and repair, and SIRT1-deﬁcient MEFs (mouse embryonic
ﬁbroblasts) exhibit a marked reduction of Rad51-, NBS1-, and
BRCA1-foci following γ-irradiation (Oberdoerffer et al., 2008;
Wang et al., 2008) (Figure 1). SIRT1 appears to be involved in
multiple DNA-repair pathways. When a DSB occurs during S or
G2 phases of the cell cycle, it will be preferentially repaired by
homologous recombination (HR) using the sister chromatid as a
template for DNA repair. SIRT1 modulates homologous recom-
bination (HR) by deacetylating WRN –the gene mutated in the
progeroid Werner Syndrome- and promoting its relocalization to
DNA lesions (Li et al., 2008), where it repairs DNA strand breaks
that arise from replication arrest. In this context, transgenic mice
expressing increased levels of SIRT1 exhibit longer telomeres and
higher frequency of sister chromatid HR events throughout the
entire genome (Palacios et al., 2010). In addition to the regula-
tion of DSB repair, SIRT1 is involved in the repair of DNA single
strand breaks as well. SIRT1 null MEFs are hyper-sensitive to
UV damage, which is mainly repaired by the nucleotide excision
repair (NER) pathway. Recent studies demonstrated that SIRT1
deacetylates two components of NER: XPA and XPC (Xeroderma
Pigmentosum A and C) upon UV damage. This deacetylation is
essential for the recognition of DNA lesions by XPA and XPC,
affecting the recruitment of downstream NER factors (Fan and
Luo, 2010; Ming et al., 2010). Overall, it appears that SIRT1 has
evolved to coordinate both proper genomic integrity and adequate
metabolic adaptation, in this way allowing cells to adapt against
stress (Figure 1). Failure on such mechanisms could clearly lead to
both metabolic diseases and tumorigenesis, as described in further
detail below.
SIRT6
The role of sirtuins in metabolism and maintenance of genomic
integrity is not restricted to SIRT1. SIRT6 deﬁcient mice appear
relatively normal at birth, but beginning at 2 weeks of age
they develop an acute degenerative phenotype, reminiscent of a
progeroid syndrome (Mostoslavsky et al., 2006). The most striking
phenotype observed in SIRT6 knockout mice is a severe hypo-
glycemia that causes death before 1month of age (Mostoslavsky
et al., 2006). Deletion of SIRT6 in mice triggers an increase in
glucose uptake that is preferentially used for glycolysis instead of
mitochondrial respiration, a metabolic switch similar to the War-
burg effect in cancer cells. Indeed, SIRT6 maintains deacetylation
of H3K9 in promoters of glycolytic genes, co-repressing Hif1α on
these promoters (Figure 1). Under conditions of nutrient scarcity,
SIRT6 is likely inactivated, causing activation of Hif1α and tran-
scription of glycolytic genes (Zhong et al., 2010). These results
support a model whereby SIRT6 works as a sensor of nutrient
availability and as a critical modulator of glucose homeostasis.
In addition to its metabolic functions, SIRT6 knockout cells
exhibit hypersensitivity to DNA-damaging agents and genomic
instability. According to the selective sensitivity among the spec-
trum of DNA damage agents tested, SIRT6 was proposed to be an
important regulator of base excision repair (BER), a mechanism
that repairs the damage of single bases in the DNA (Mostoslavsky
et al., 2006). Interestingly, in human cells, SIRT6 appears to reg-
ulate repair of DNA DSBs as well. Together with ATM and ATR,
DNA-dependent protein kinase (DNA-PK) is a sensor of DSBs,
promoting DNA repair by NHEJ. SIRT6 stabilizes DNA-PK at
DSBs promoting repair (McCord et al., 2009). Notably, HR is
prompted by the resection of a DSB through the action of different
proteins like CtIP and PARP1, in turn generating single-stranded
DNA that will invade the homologous strand for repair. SIRT6 has
been shown to bind to DSBs and deacetylate CtIP. Although the
mechanism remains unclear, deacetylation of CtIP would enhance
the resection of the DSB, promoting HR (Kaidi et al., 2010). In
human cancer cell lines, SIRT6 deacetylation of H3K9 at telomeres
promotes the stable association of WRN protein at these regions,
critical for the processing of telomeres during S phase. Thus,
SIRT6 downregulation leads to telomere dysfunction and prema-
ture senescence, as in Werner Syndrome cells (Michishita et al.,
2008). Finally, recent studies have demonstrated that upon oxida-
tive stress, SIRT6 associates with PARP1 at theDSBs and stimulates
its activity through ADP-ribosylation. PARP1 activity will pro-
mote NHEJ as well as HR repair (Mao et al., 2011). This evidence
suggests an additional mechanism for SIRT6-mediated genome
protection during stress. While studies in vitro have implicated
SIRT6 in several DNA repair pathways (Figure 1), a protective role
for SIRT6 in vivo remains as yet poorly understood, and future
genetic studies in mice will be needed to obtain a clearer picture.
SIRT3
SIRT3 works as the major protein deacetylase within the
mitochondrial matrix (Lombard et al., 2007) (Figure 1). In low
nutrient conditions, SIRT3 stimulates alternative pathways for
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FIGURE 1 | Sirtuins’ regulation of DNA repair and metabolism. Diagram
indicating the main DNA repair and metabolic pathways regulated by SIRT1,
SIRT3, and SIRT6 in the nucleus and in the mitochondria. Activating and
inhibitory functions are depicted in green and red, respectively.
energy production in the mitochondria. On one hand, SIRT3
functions as a positive modulator of fatty-acid oxidation through
deacetylation of long-chain acyl coenzyme A dehydrogenase
(LCAD; Hirschey et al., 2010). In parallel, SIRT3 helps to detoxify
the ammonia generated during amino acid catabolism promoting
the urea cycle through the deacetylation of ornithine transcar-
bamoylase (OTC), the enzyme that catalyzes the second step in
the urea cycle (Hallows et al., 2011). Finally, it promotes acetate
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recycling by activating acetyl-CoA synthetase 2 (AceCS2), the
enzyme that converts acetate into acetyl-CoA, that can now enter
theTCAcycle (Hallows et al., 2006; Schwer et al., 2006).Under fast-
ing, low-carbohydrate diet as well as in diabetic patients, ketone
bodies produced in the liver are used by the brain and skele-
tal muscle as main energy sources. SIRT3 promotes ketone body
production from fatty-acid oxidation by deacetylating 3-hydroxy-
3-methylglutaryl-CoA synthase (HMGCS2) (Shimazu et al., 2010)
(Figure 1).
Although SIRT3 is mainly mitochondrial, and therefore no role
in protection of the genome could be presumed for this sirtuin,
SIRT3-deﬁcient MEFs exhibit increased cellular superoxide lev-
els and chromosomal instability when stressed (Kim et al., 2010).
In fact, metabolic functions of SIRT3 are closely coupled with a
protective role against oxidative damage. SIRT3 decreases mito-
chondrial reactive oxygen species (ROS) generated upon cellular
stress by regulating the expression and activity of MnSOD, the
main scavenger of superoxide in the mitochondria (Kim et al.,
2010;Qiu et al., 2010; Tao et al., 2010; Chen et al., 2011) (Figure 1).
This seems to play a key role in the cellular response against calo-
rie restriction, where SIRT3 reduces oxidative stress by enhancing
glutathione antioxidant defense mechanisms through deacetyla-
tion of Idh2 (Someya et al., 2010). Moreover, SIRT3 regulates the
electron transport chain Complex III, that can direct ROS out of
the mitochondria and into both the matrix and the cytoplasm
(Kim et al., 2010). In this manner, SIRT3 management of ROS
from mitochondria at different levels might protect the cell from
oxidative damage, in turn inhibiting genomic instability.
The aforementioned roles of sirtuins in DNA repair, together
with their ability to regulate both glucose homeostasis and ROS
levels suggest the possibility that these sirtuins may act as putative
tumor suppressors, as discussed in detail below.
SIRTUINS IN CANCER
The ﬁrst evidences linking SIRT1 and tumorigenesis came from
two cell-based studies, which uncovered the ability of SIRT1 to
deacetylate and inhibit the tumor suppressor p53 (Luo et al., 2001;
Vaziri et al., 2001). In this manner, SIRT1 promotes cell survival
under stress conditions by speciﬁcally repressing p53 dependent
apoptosis. However, as we alreadymentioned, an increase in SIRT1
associates with enhanced DNA repair, so this phenomena could
also be a protecting mechanism to give priority to repair over
apoptosis. SIRT1 regulation of p53 was conﬁrmed in vivo in SIRT1
knockout mice that exhibit hyperacetylation of p53 and increased
apoptosis of thymocytes afterDNAdamage (Cheng et al., 2003). In
this context, it would be interesting to explore if the enhancement
of p53 activity could as well be secondary to increased DNA dam-
age in the absence of SIRT1. In addition, SIRT1 knockout mice
did not show enhanced p21 induction or sensitivity upon DNA
damage, suggesting that only the apoptotic function of p53 is reg-
ulated by SIRT1 (Cheng et al., 2003). Although SIRT1-mediated
deacetylation of p53 has been conﬁrmed by other groups, the
biological relevance is a matter of debate, since alterations in
p53 biological activities have not been observed in the absence
of SIRT1 in vivo (Kamel et al., 2006). Thus, the role for SIRT1
on p53-mediated tumor suppression still remains to be eluci-
dated. In humans, SIRT1 expression is higher in several types of
cancer, including acute myeloid leukemia, primary colon cancer,
prostate cancers, and non-melanoma skin cancers (reviewed in
Deng, 2009), suggesting again a potential role of SIRT1 as an
oncogene. This result is also true for several cell lines. Deple-
tion of SIRT1 induces growth arrest and reduces drug resistance
of cancer cells in vitro (Ota et al., 2006; Liang et al., 2008) and
increases tumor cell death with no toxic effects in normal cells
in culture (Ford et al., 2005) proposing SIRT1 as a potential tar-
get in cancer therapy. Also, overexpression or activation of SIRT1
promotes cellular proliferation, impairs cellular senescence and
increases growth rate via ERK/S6K1 signaling pathway (Huang
et al., 2008). SIRT1 overexpression also represses epigenetically the
activity or expression of tumor suppressor and DNA repair genes
including FOXO family members (FOXO1, FOXO3a, and FOXO4)
(Motta et al., 2004), p73 (Dai et al., 2007), Rb (Wong and Weber,
2007), MLH1 (Pruitt et al., 2006), and Ku70 (Cohen et al., 2004).
Reciprocally, the activity or expression of SIRT1 is inhibited by at
least two tumor suppressor genes; the transcriptional repressors
HIC1 (hypermethylated in cancer-1) and DBC1 (deleted in breast
cancer-1; Chen et al., 2005; Kim et al., 2008; Zhao et al., 2008).
The current data available for SIRT1 expression in cancer con-
trasts with previous hypothesis pointing toward a role for SIRT1
as a tumor suppressor. Although a variety of cancer cell lines show
SIRT1 overexpression, SIRT1 expression is reduced in different
human cancers, like glioblastoma, bladder carcinoma, prostate
carcinoma, and ovarian cancer (Wang et al., 2008). Moreover, an
increase in SIRT1 levels has been shown to inhibit growth of BRCA
mutant tumors in vivo. Thus far, the data from cell-based studies
do not clear up whether SIRT1 acts as an oncogene or a tumor
suppressor. Only the generation of mice with genetically modiﬁed
SIRT1 is ﬁnally shedding some light on this matter.
The studies of cancer in mouse models of SIRT1 support the
idea that SIRT1 has, indeed, a tumor suppressor activity. In can-
cer prone mouse models, like p53+/− and APC+/min mice, SIRT1
expression protects from tumor development. Increased expres-
sion of SIRT1 has been shown to protect from ionizing radiation-
induced cancer in p53+/− mice (Oberdoerffer et al., 2008) whereas
SIRT1+/− p53+/− mice show an earlier onset of tumor develop-
ment in comparison to SIRT1+/+ p53+/− littermates (Oberdoerf-
fer et al., 2008). It has been proposed that SIRT1 relocalization to
DNA breaks represses transcription of these regions and promotes
repair (Oberdoerffer et al., 2008), protecting from genome insta-
bility. A different mechanism underlies SIRT1 protection from
intestinal tumors in theAPC+/min mouse,where SIRT1 expression
promotes the cytoplasmic relocalization of the oncogenic form of
β-catenin inhibiting its ability to activate transcription and drive
cell proliferation (Firestein et al., 2008). Herranz and colleagues
demonstrated that SIRT1 overexpression provides strong protec-
tion against metabolic syndrome-associated liver cancer by reduc-
ing DNA damage and by preventing inﬂammation and fatty liver.
In addition, they demonstrated that a mild increase in SIRT1 lev-
els protects mice from spontaneous and aging-associated cancers
(Herranz et al., 2010). Additionally, a recent work demonstrated
that overexpression of SIRT1 reduces growth and angiogenesis of
xenograft tumors through the interaction and repression of Hif1α
(Lim et al., 2010).
Despite the important role of SIRT6 in maintaining genome
stability and energy metabolism, it remains as yet unexplored
whether SIRT6 plays a role in tumorigenesis. There are no studies
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Table 1 | Sirtuins in cancer.
Sirtuin Cell-based studies and xenografts Mouse models Human tumors
SIRT1 • Deacetylates p53 and inhibits apoptosis
(Luo et al., 2001; Vaziri et al., 2001)
• SIRT1-transgenic mouse have
reduced incidence of spontaneous
and aging related cancers
(sarcomas and carcinomas;
Herranz et al., 2010)
• Overexpressed in acute myeloid
leukemia, colon cancer, prostate
cancer, non-melanoma skin
cancer (revised in Deng, 2009).
• Overexpression or activation of SIRT1
promotes proliferation, bypasses cellular
senescence and increases growth rate via
ERK/S6K1 (Huang et al., 2008) • SIRT1 expression in the intestine in
APC+/min mice protects from
intestinal tumor formation
(Firestein et al., 2008)
• Reduced expression in
glioblastoma, bladder carcinoma,
prostate carcinoma, and ovarian
cancer (Wang et al., 2008)
•Two tumor suppressors regulate negatively
SIRT1: HIC1 and DBC1 (Chen et al., 2005;
Zhao et al., 2008; Kim et al., 2008)
• SIRT1+/− p53+/− mice show earlier
development of sarcomas and
lymphomas associated with p53
deﬁciency (Oberdoerffer et al.,
2008)
• Expression of SIRT1 reduces growth and
angiogenesis of xenograft tumors (Lim
et al., 2010)
SIRT3 • Absence of SIRT3 promotes transformation
of Ras-infected MEFs (Kim et al., 2010)
• SIRT3 knockout mice show higher
incidence of spontaneous
mammary tumors (Kim et al., 2010)
• Overexpressed in breast cancer
and oral squamous cell carcinoma
(Ashraf et al., 2006)• Decreases cellular ROS levels by regulating
MnSOD (Qiu et al., 2010; Tao et al., 2010) • Reduced expression in breast
cancer (Finley et al., 2011)
SIRT6 • Unknown • Unknown • SIRT6 deletions in acute myeloid
leukemias (Mahlknecht et al.,
2006)
about SIRT6 expression in human cancer either, besides the obser-
vation that SIRT6 chromosomal locus is a regionprone to chromo-
somal breaks in human acutemyeloid leukemia (Mahlknecht et al.,
2006). It has been recently shown that overexpression of SIRT6
induces apoptosis in cancer cell lines but not in non-transformed
cells through its ADP-ribosyltransferase activity, suggesting that
SIRT6 could be a target for overexpression in cancer therapy (Van
Meter et al., 2011).
Increased levels of SIRT3 associate with node-positive breast
cancer versus non-malignant breast tissue (Ashraf et al., 2006)
as well as with oral squamous cell carcinoma, suggesting that
SIRT3 could function as a tumor promoter. However, studies in
geneticallymodiﬁedmousemodels of SIRT3question this hypoth-
esis. SIRT3-deﬁcient MEFs are transformed by the expression of a
single oncogene (Ras) whereas wildtype MEFs also require inac-
tivation of a tumor-suppressor gene. In addition, loss of SIRT3
in vivo results in a mild tumor proneness; higher incidence of
spontaneous mammary tumors in 24months old mice (Kim et al.,
2010). How SIRT3 protects from tumorigenesis is a matter of
debate. A current hypothesis poses that SIRT3 tumor suppres-
sive role comes from its ability to regulate cellular ROS levels, an
idea that ﬁts in the free radical theory that proposes the accumu-
lation of oxidative stress as a major cause of ageing and cancer.
Such a model is clearly supported by the above mentioned role for
SIRT3 in regulating MnSOD (Kim et al., 2010; Qiu et al., 2010;
Tao et al., 2010; Chen et al., 2011). However, the recent observa-
tion that SIRT3-deﬁcient cells become highly glycolytic, suggests
another possibility (Bell et al., 2011; Finley et al., 2011). SIRT3
loss generates an increase in cellular ROS that would stabilize
Hif1α. Stabilization of Hif1α, as it occurs in SIRT6-null cells,
will lead to a metabolic reprogramming where cells will priori-
tize glycolysis over oxidative phosphorylation, a shift that confers
metabolic advantages in highly proliferative cells. Therefore, it has
been suggested that SIRT3 works as a tumor suppressor by oppos-
ing reprogramming of cancer cell metabolism (Bell et al., 2011;
Finley et al., 2011), in other words, repressing the Warburg effect.
According to a tumor suppressive role for this sirtuin, expression
of SIRT3 was found signiﬁcantly reduced in human breast cancer
samples (Finley et al., 2011). It remains to be determined whether
oxidative stress or glycolytic metabolism plays a dominant role in
this phenotype.
SIRTUINS: TUMOR SUPPRESSORS OR ONCOGENES
The above-discussed results suggest that SIRT1 and SIRT3 are
tumor suppressor genes. In the multistep development of cancer,
loss of SIRT1 or SIRT3 might be a late phenomenon in carcino-
genesis allowing the growing tumor to evade apoptosis or acquire
different metabolic requirements. Thus, SIRT1 and SIRT3 might
be lost in late stages of tumor progression, conferring prolifera-
tive advantage to cells with already multiple genetic alterations.
In addition, the analysis of updated databases (such as Oncomine
andTumorscape), as well as upcoming results fromour laboratory,
appears to suggest that SIRT6 is downregulated in tumors, there-
fore functioning as a tumor suppressor as well (Table 1). Much
workwill be needed to pinpoint the precisemolecularmechanisms
governing sirtuins’ functions in cancer. But one thing is sure: these
proteins clearly link DNA repair and metabolism, two hallmarks
of cancer. As such, it is tempting to envision that modulators of
sirtuin activity could provide future beneﬁcial alternatives against
this devastating disease.
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